EverGen Infrastructure Reports Strong Q1 2026 Earnings Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Yahoo Finance
- Significant Revenue Growth: EverGen Infrastructure reported a 38% year-over-year revenue increase to $2.6 million in Q1 2026, although it saw a decline compared to Q4 2025, indicating strong market performance.
- Debt Restructuring Impact: The company successfully restructured its debt, moving approximately $13 million from corporate to asset level, saving about $500,000 annually in debt service costs, thereby enhancing flexibility for future growth.
- Long-Term Contract Assurance: The 20-year offtake agreement with FortisBC provides a stable revenue base, ensuring long-term revenue certainty and delivering consistent returns for shareholders.
- Sustained Production Capacity: RNG production remained steady at 200,000 gigajoules in Q1 2026, demonstrating strong operational performance despite the lengthy permitting process for expansion projects, which positions the company competitively in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVGN
Wall Street analysts forecast EVGN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.610
Low
2.50
Averages
2.50
High
2.50
Current: 0.610
Low
2.50
Averages
2.50
High
2.50
About EVGN
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EverGen Infrastructure Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: EverGen Infrastructure reported a 38% year-over-year revenue increase to $2.6 million in Q1 2026, although it saw a decline compared to Q4 2025, indicating strong market performance.
- Debt Restructuring Impact: The company successfully restructured its debt, moving approximately $13 million from corporate to asset level, saving about $500,000 annually in debt service costs, thereby enhancing flexibility for future growth.
- Long-Term Contract Assurance: The 20-year offtake agreement with FortisBC provides a stable revenue base, ensuring long-term revenue certainty and delivering consistent returns for shareholders.
- Sustained Production Capacity: RNG production remained steady at 200,000 gigajoules in Q1 2026, demonstrating strong operational performance despite the lengthy permitting process for expansion projects, which positions the company competitively in the market.
See More
Evogene's BMC128 Phase 1 Clinical Trial Shows Promising Results
- Successful Clinical Trial: Evogene has completed the first-in-human Phase 1 clinical trial of BMC128, enrolling 11 patients, with results indicating a favorable safety profile and high tolerability, as no dose-limiting toxicities were observed, marking a significant milestone for the product's potential in tumor immunotherapy.
- Preliminary Anti-Tumor Activity: Among the 11 patients, 5 achieved stable disease after 16 weeks of combination treatment, and 1 patient experienced a partial response, demonstrating early signs of anti-tumor activity for BMC128 when used alongside immune checkpoint inhibitors, potentially offering new hope for future treatments.
- Biomarker Analysis: Clinical observations aligned with translational analyses, showing increased microbiome diversity and significant evidence of immune activation in responding patients, supporting the proposed mechanism of action for BMC128 and laying a foundation for future clinical applications.
- Strategic Partnership Advancement: Evogene has entered into a licensing agreement with Lishan Biotech to further develop BMC128, reflecting the company's confidence in microbiome-based therapies for cancer treatment and indicating an acceleration in the planning for subsequent clinical development stages.
See More
Evogene Reports Q1 2026 Financial Results and Strategic Developments
- Financial Overview: Evogene reported revenues of $334,000 for Q1 2026, a significant drop from $2.34 million in Q1 2025, indicating challenges in revenue growth that may impact investor confidence.
- R&D Collaboration Expansion: The company announced three new collaborations in the pharmaceutical sector, bringing the total to four, demonstrating Evogene's ongoing commitment to advancing small-molecule discovery and optimization despite its poor financial performance.
- Agricultural Project Progress: The AgPlenus subsidiary is advancing novel herbicide programs through collaboration with Corteva, while its internal fungicide program shows strong progress, highlighting the effective integration of AI-driven design with experimental validation, potentially providing a competitive edge in the market.
- Strategic Transformation and Outlook: Following the strategic transformation initiated in 2025, Evogene is now focused on execution, expecting to support long-term growth through enhanced technological collaborations and product pipeline expansion, despite currently facing financial losses.
See More
Evogene Reports Q1 Earnings Miss with Significant Revenue Decline
- Earnings Performance: Evogene's Q1 GAAP EPS of -$0.60 misses expectations by $0.33, indicating significant challenges in profitability that could undermine investor confidence moving forward.
- Revenue Decline: The company reported revenue of $0.3M for the quarter, a staggering 100% year-over-year decline, falling short of the $0.05M forecast, reflecting severe market competition that may complicate future financing efforts.
- Cash Flow Situation: As of March 31, 2026, Evogene held approximately $13.1 million in cash and cash equivalents, with cash usage of about $2.8 million in Q1, highlighting increasing pressure on the company to maintain operations amid financial strain.
- Market Reaction Outlook: Given the poor financial performance, Evogene may face further scrutiny from Nasdaq, prompting investors to closely monitor the company's future financing and strategic adjustments to navigate its current financial challenges.
See More
Evogene to Announce Q1 Earnings on May 20
- Earnings Announcement Date: Evogene (EVGN) is set to announce its Q1 2023 earnings on May 20 before market open, with significant attention on its performance and future outlook.
- Expected Financial Metrics: Analysts project an EPS of -$0.27, reflecting a 28.9% year-over-year improvement, while revenue is estimated at $0.35 million, indicating a 100% year-over-year decline, highlighting the challenges the company faces.
- Historical Performance Review: Over the past two years, Evogene has beaten EPS estimates 63% of the time and revenue estimates 50% of the time, indicating a degree of volatility in its financial performance.
- Market Reaction Anticipation: Investors will closely monitor the upcoming earnings report to assess Evogene's financial health and competitiveness in the biotechnology sector, particularly in light of its performance in the current market environment.
See More
Evogene Faces Nasdaq Compliance Risk After Share Price Drop
- Compliance Risk Notification: Evogene Ltd. received a notice from Nasdaq indicating non-compliance with Rule 5550(a)(2) after its shares closed below $1.00 for 30 consecutive business days, potentially leading to delisting risks.
- Compliance Deadline: The company must regain compliance by September 28, 2026, requiring its shares to close at or above $1.00 for at least 10 consecutive business days within a 180-day period, which is critical for its financing and market confidence.
- Response Measures: Evogene stated it would consider options, including a potential reverse stock split, to regain compliance, demonstrating its commitment to maintaining its Nasdaq listing.
- Market Reaction: Following the announcement, Evogene's shares fell by 3.16%, reflecting investor concerns about the company's ability to regain compliance, which could impact its financing capabilities and market image.
See More
EverGen Infrastructure Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: EverGen Infrastructure reported a 38% year-over-year revenue increase to $2.6 million in Q1 2026, although it saw a decline compared to Q4 2025, indicating strong market performance.
- Debt Restructuring Impact: The company successfully restructured its debt, moving approximately $13 million from corporate to asset level, saving about $500,000 annually in debt service costs, thereby enhancing flexibility for future growth.
- Long-Term Contract Assurance: The 20-year offtake agreement with FortisBC provides a stable revenue base, ensuring long-term revenue certainty and delivering consistent returns for shareholders.
- Sustained Production Capacity: RNG production remained steady at 200,000 gigajoules in Q1 2026, demonstrating strong operational performance despite the lengthy permitting process for expansion projects, which positions the company competitively in the market.
See More
Evogene's BMC128 Phase 1 Clinical Trial Shows Promising Results
- Successful Clinical Trial: Evogene has completed the first-in-human Phase 1 clinical trial of BMC128, enrolling 11 patients, with results indicating a favorable safety profile and high tolerability, as no dose-limiting toxicities were observed, marking a significant milestone for the product's potential in tumor immunotherapy.
- Preliminary Anti-Tumor Activity: Among the 11 patients, 5 achieved stable disease after 16 weeks of combination treatment, and 1 patient experienced a partial response, demonstrating early signs of anti-tumor activity for BMC128 when used alongside immune checkpoint inhibitors, potentially offering new hope for future treatments.
- Biomarker Analysis: Clinical observations aligned with translational analyses, showing increased microbiome diversity and significant evidence of immune activation in responding patients, supporting the proposed mechanism of action for BMC128 and laying a foundation for future clinical applications.
- Strategic Partnership Advancement: Evogene has entered into a licensing agreement with Lishan Biotech to further develop BMC128, reflecting the company's confidence in microbiome-based therapies for cancer treatment and indicating an acceleration in the planning for subsequent clinical development stages.
See More
Evogene Reports Q1 2026 Financial Results and Strategic Developments
- Financial Overview: Evogene reported revenues of $334,000 for Q1 2026, a significant drop from $2.34 million in Q1 2025, indicating challenges in revenue growth that may impact investor confidence.
- R&D Collaboration Expansion: The company announced three new collaborations in the pharmaceutical sector, bringing the total to four, demonstrating Evogene's ongoing commitment to advancing small-molecule discovery and optimization despite its poor financial performance.
- Agricultural Project Progress: The AgPlenus subsidiary is advancing novel herbicide programs through collaboration with Corteva, while its internal fungicide program shows strong progress, highlighting the effective integration of AI-driven design with experimental validation, potentially providing a competitive edge in the market.
- Strategic Transformation and Outlook: Following the strategic transformation initiated in 2025, Evogene is now focused on execution, expecting to support long-term growth through enhanced technological collaborations and product pipeline expansion, despite currently facing financial losses.
See More
Evogene Reports Q1 Earnings Miss with Significant Revenue Decline
- Earnings Performance: Evogene's Q1 GAAP EPS of -$0.60 misses expectations by $0.33, indicating significant challenges in profitability that could undermine investor confidence moving forward.
- Revenue Decline: The company reported revenue of $0.3M for the quarter, a staggering 100% year-over-year decline, falling short of the $0.05M forecast, reflecting severe market competition that may complicate future financing efforts.
- Cash Flow Situation: As of March 31, 2026, Evogene held approximately $13.1 million in cash and cash equivalents, with cash usage of about $2.8 million in Q1, highlighting increasing pressure on the company to maintain operations amid financial strain.
- Market Reaction Outlook: Given the poor financial performance, Evogene may face further scrutiny from Nasdaq, prompting investors to closely monitor the company's future financing and strategic adjustments to navigate its current financial challenges.
See More
Evogene to Announce Q1 Earnings on May 20
- Earnings Announcement Date: Evogene (EVGN) is set to announce its Q1 2023 earnings on May 20 before market open, with significant attention on its performance and future outlook.
- Expected Financial Metrics: Analysts project an EPS of -$0.27, reflecting a 28.9% year-over-year improvement, while revenue is estimated at $0.35 million, indicating a 100% year-over-year decline, highlighting the challenges the company faces.
- Historical Performance Review: Over the past two years, Evogene has beaten EPS estimates 63% of the time and revenue estimates 50% of the time, indicating a degree of volatility in its financial performance.
- Market Reaction Anticipation: Investors will closely monitor the upcoming earnings report to assess Evogene's financial health and competitiveness in the biotechnology sector, particularly in light of its performance in the current market environment.
See More
Evogene Faces Nasdaq Compliance Risk After Share Price Drop
- Compliance Risk Notification: Evogene Ltd. received a notice from Nasdaq indicating non-compliance with Rule 5550(a)(2) after its shares closed below $1.00 for 30 consecutive business days, potentially leading to delisting risks.
- Compliance Deadline: The company must regain compliance by September 28, 2026, requiring its shares to close at or above $1.00 for at least 10 consecutive business days within a 180-day period, which is critical for its financing and market confidence.
- Response Measures: Evogene stated it would consider options, including a potential reverse stock split, to regain compliance, demonstrating its commitment to maintaining its Nasdaq listing.
- Market Reaction: Following the announcement, Evogene's shares fell by 3.16%, reflecting investor concerns about the company's ability to regain compliance, which could impact its financing capabilities and market image.
See More
